Loading...
Loading...
MDGL| Name | Value |
|---|---|
| Revenues | 287.3M |
| Cost of Revenue | 18.1M |
| Gross Profit | 269.1M |
| Operating Expense | 383.1M |
| Operating I/L | -114.0M |
| Other Income/Expense | -0.2M |
| Interest Income | 10.3M |
| Pretax | -114.2M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -114.2M |
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in therapeutic candidates for cardiovascular, metabolic, and liver diseases. Their lead product, resmetirom, is a liver-directed selective thyroid hormone receptor-ß agonist currently in Phase III clinical trials for non-alcoholic steatohepatitis treatment. Additionally, the company is developing MGL-3745 as a backup compound to resmetirom. Madrigal Pharmaceuticals has a research, development, and commercialization agreement with Hoffmann-La Roche, positioning them to generate revenue through the successful development and commercialization of their therapeutic candidates.
